PT-141 human studies: what the bremelanotide trials show

Last updated 2026-07-24

What are the main PT-141 human studies people cite?

The core evidence base for PT-141 (its generic name is bremelanotide, sold as Vyleesi) comes from two identical phase 3 randomized, placebo-controlled trials known together as RECONNECT, published in Obstetrics and Gynecology in 2019 ^[1]. These enrolled premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) and ran for 24 weeks, with women self-injecting either bremelanotide or placebo subcutaneously before anticipated sexual activity. Before RECONNECT, a phase 2b dose-ranging study established the 1.75 mg subcutaneous dose that eventually became the approved Vyleesi dose, based on responder analyses across several dose levels ^[2]. There's also older pharmacology work going back to 2006 and earlier, when bremelanotide was still being explored as a nasal spray before the injection version took over development ^{[3] [4]}. A 2022 paper pooled subgroup data across both RECONNECT trials to check whether results held up across different ages, HSDD severity levels, and background health conditions ^[5]. That kind of prespecified subgroup work matters because a single averaged result can hide a drug that works great for some people and does nothing for others. For a plain-language look at the compound itself outside the trial data, see PT-141 peptide.

What is PT-141 (bremelanotide) actually FDA-approved for?

Bremelanotide is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. That approval came in 2019 ^[6]. HSDD is diagnosed when a person has persistent, distressing low sexual desire that isn't better explained by a relationship problem, another medical condition, or medication side effects ^[7]. This is a narrow approval. It is not approved for postmenopausal women, for men, or for low desire that isn't causing personal distress. A 2020 pharmacotherapy review published in The Annals of Pharmacotherapy walks through exactly how that indication was defined and why the label is limited to premenopausal women ^[8]. It's worth being blunt here: this is a prescription drug for a specific diagnosis, not a general arousal booster. The trials were built around that diagnosis, and the approval only covers it ^{[6] [9]}.

How well did PT-141 actually work in the RECONNECT trials?

In the RECONNECT trials, women on bremelanotide reported statistically significant improvements in desire scores (measured with the Female Sexual Function Index desire domain) and reductions in distress related to low desire, compared to placebo, over 24 weeks ^[1]. But the word "significant" here is a statistics term, not a promise of a dramatic personal experience. A widely discussed 2024 reanalysis in the Journal of Sex Research argued that the actual effect sizes in RECONNECT were small, and questioned whether the improvement over placebo was large enough to matter to most patients day to day ^[10]. A separate 2021 reanalysis in the same journal raised similar concerns about how "responder" was defined in the original trial reporting . So you end up with two things being true at once: the trials met their statistical bar for FDA approval, and independent researchers still think the real-world benefit is modest ^[10] . A 2021 piece in Drug and Therapeutics Bulletin went further, comparing bremelanotide's approval pathway to flibanserin's and questioning whether either drug's approval reflected an effect size worth the side effect burden ^[11]. Here's the honest takeaway: PT-141 beat placebo in controlled trials. It did not produce huge, obvious jumps in desire for the average participant. Anyone expecting a dramatic on/off switch is going to be disappointed.

How does PT-141 work in the brain, and how is that different from Viagra-type drugs?

This is the single most important thing to understand about PT-141, and most people get it wrong. Bremelanotide does not work on blood vessels. It works on the brain. Sildenafil (Viagra) and similar drugs work on the vascular system: they relax smooth muscle and increase blood flow to genital tissue. Bremelanotide instead activates melanocortin receptors, mainly MC4R, in the central nervous system, which is believed to influence dopamine pathways tied to sexual motivation and desire ^{[12] [13]}. A 2022 review in CNS Spectrums lays out this neurobiology specifically for HSDD treatment, describing how melanocortin receptor activation in the hypothalamus is thought to drive the desire response rather than any local genital effect ^[13]. That central mechanism explains why bremelanotide is dosed on an as-needed basis before anticipated sexual activity rather than daily, and why its side effects (nausea, flushing, headache) look more like a brain and gut response than a circulatory one ^{[1] [4]}. It also explains why bremelanotide doesn't require any kind of physical arousal or stimulation to "work" in the way a vascular drug does; the theory is that it shifts motivation and desire signaling upstream in the brain, before the body's arousal response even starts ^[13]. The melanocortin system itself isn't unique to sexual desire. It's also central to appetite and metabolic regulation, which is why researchers have looked at melanocortin receptor agonists for obesity and metabolic disease too ^[4]. That overlap is also why bremelanotide trials tracked body weight as a side effect, more than as a side note (more on that below).

What side effects showed up in the human trials?

Nausea is the headline side effect, and it's common enough that every patient should be told about it clearly before starting. A pooled safety analysis across the full bremelanotide clinical development program found nausea affected a large share of participants, with rates cited around 40% in trial populations, and flushing affected roughly 20% ^[14]. | Side effect | Approximate rate in trials |

Does PT-141 affect body weight or appetite?

Because bremelanotide acts on the same melanocortin system involved in appetite regulation, researchers specifically checked what happens to body weight during treatment. A 2022 paper in Diabetes, Obesity and Metabolism analyzed data from two phase 1 randomized controlled trials in obese women and reported modest weight changes associated with bremelanotide exposure . This wasn't the primary purpose of those trials and shouldn't be read as evidence that bremelanotide is a weight loss treatment; it's approved for HSDD, full stop. But the finding lines up with the broader research interest in melanocortin receptor agonists for metabolic disorders, an area reviewed more broadly in a 2023 Nature Reviews Endocrinology paper on central melanocortin targets ^[4]. If you're curious why a libido drug and an obesity drug target overlapping biology, that's the answer: same receptor family, different downstream effect depending on which brain circuit gets activated.

How is PT-141 dosed in the studies versus real-world use?

In the RECONNECT trials, the studied dose was 1.75 mg delivered by subcutaneous autoinjector, taken as needed at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and a general trial guidance of no more than 8 doses per month ^{[1] [9]}. That's the FDA-approved Vyleesi regimen. Earlier phase 2b dose-ranging work tested a range of doses to find the point where effectiveness and tolerability balanced out, and 1.75 mg is what came out the other side as the approved dose ^[2]. Going higher generally means more nausea without proportionally more benefit, based on that dose-response data ^[2]. If you're trying to understand dosing schedules, timing before activity, and monthly limits in more detail, PT-141 dosage chart and PT-141 dosage calculator break down the numbers further. For practical injection technique and timing questions, PT-141 peptide how to use covers the mechanics.

Who was excluded from the PT-141 trials, and why does that matter?

The RECONNECT trials specifically enrolled premenopausal women with a confirmed HSDD diagnosis, and excluded women with other identifiable causes of low desire, such as relationship distress alone, depression as the primary driver, or another medical condition better explaining the symptom ^{[1] [7]}. That's a clinically important distinction because HSDD as a diagnosis, described in detail in a 2021 review in the Journal of Midwifery & Women's Health, requires ruling out those other causes first ^[7]. This means the trial data doesn't tell you how bremelanotide performs in postmenopausal women, men, or people whose low desire is tied to a relationship issue or an untreated mood disorder. A 2022 review in Current Psychiatry Reports on pharmacotherapy for sexual dysfunction in women makes the point that treatment choice depends heavily on getting the underlying cause right first, since a drug aimed at central desire pathways won't fix a problem rooted somewhere else ^[16]. Uncontrolled hypertension and cardiovascular disease were also exclusion criteria, consistent with the blood pressure concerns already discussed ^[15].

How does PT-141 compare to flibanserin (Addyi), the other HSDD drug?

Flibanserin (Addyi) was approved first, in 2015, and works differently: it's a daily pill that acts on serotonin and dopamine receptor balance in the brain, taken every night regardless of sexual activity. Bremelanotide is as-needed and injectable, targeting melanocortin receptors instead ^{[12] [9]}. A 2021 Drug and Therapeutics Bulletin analysis compared the two approvals directly and argued that both drugs cleared the FDA bar with effect sizes that some clinicians and researchers consider clinically marginal, raising the broader question of whether the regulatory standard for HSDD drugs is set too low ^[11]. That's a fair criticism to know about going in: neither drug is a slam dunk, and picking between them often comes down to which side effect profile and dosing schedule a person can tolerate, rather than one being dramatically more effective than the other. A 2022 review in The Urologic Clinics of North America frames both drugs as one part of a broader toolkit for female sexual dysfunction that also includes non-drug approaches like counseling and pelvic floor therapy, not a standalone fix ^[9].

Does PT-141 interact with alcohol or other medications?

The Vyleesi label and related pharmacology reviews note that bremelanotide can delay gastric emptying, which has implications for other oral medications taken around the same time, and it's not recommended to combine bremelanotide with naltrexone, since naltrexone can blunt the drug's central mechanism ^{[9] [17]}. Alcohol isn't specifically flagged as dangerous in combination the way it might be with some other medications, but nausea risk is already high on its own, and alcohol won't help that. Because bremelanotide raises blood pressure transiently after each dose, anyone taking blood pressure medication should discuss timing and monitoring with a prescriber rather than assuming it's a non-issue ^[15]. This is exactly the kind of interaction question that's easy to overlook when people source peptides outside a clinical relationship, which is part of why provider oversight matters here, more than for getting a prescription but for catching interactions before they cause a problem.

Is there research on PT-141 outside of sexual desire?

Yes, and it's worth knowing about even though none of it is an approved use. Because bremelanotide acts on melanocortin receptors broadly, researchers have looked at it in contexts far outside HSDD. A 2024 study in Anticancer Research found that bremelanotide induced cell death and growth inhibition in glioblastoma cells in laboratory experiments, tied to suppression of a protein called survivin . That's early lab-level cancer biology research, not a treatment, and it says nothing about safety or effectiveness in actual cancer patients. Separately, melanocortin receptor genetics have been studied for their link to inflammatory traits and disease susceptibility, an area a 2025 review in Diseases covered in depth ^[18]. And drug delivery researchers have experimented with alternative ways to get peptides like bremelanotide into the body, including a 2025 study on a dissolvable patch for transbuccal (through the cheek) peptide delivery, aimed at avoiding injections altogether . None of this changes what bremelanotide is approved for today. It's context for why the compound keeps showing up in research papers that have nothing to do with libido.

What don't we know yet about PT-141 from human studies?

Long-term data beyond the trial periods (24 weeks in RECONNECT, with some extension safety data) is thin, and neither reanalysis paper found evidence of long-term study beyond a year or two of exposure in the published record ^{[1] [10]} . We also don't have solid trial data in postmenopausal women, men, or people using it off-label outside the approved diagnosis, since those groups were excluded from the core trials by design ^{[1] [7]}. There's also genuine scientific disagreement about how meaningful the effect size is. The FDA approved bremelanotide based on statistically significant results, but independent reanalyses in the Journal of Sex Research have questioned whether those results translate into an experience most patients would call clearly better, more than numerically different ^[10] . That's not a hidden fact, it's published, peer-reviewed pushback sitting right next to the approval data, and a responsible summary has to hold both at once. If you're deciding whether to try it, the honest framing is: it has real trial evidence behind a narrow indication, it comes with a meaningful nausea burden, and reasonable researchers disagree about how big the benefit really is ^{[1] [14] [10]}.

How should someone act on this evidence?

If you have a HSDD diagnosis, or symptoms that sound like it, the trial evidence supports bremelanotide as one legitimate option, alongside flibanserin and non-drug approaches, best worked through with a prescriber who can check your blood pressure history and medication list first ^{[9] [15]}. This isn't a drug to source casually; the trial data on nausea and blood pressure effects means dosing and monitoring benefit from actual clinical oversight, not guesswork. Bremelanotide Rx covers the provider-reviewed route to bremelanotide, connecting the clinical evidence above to a path where a licensed provider reviews your history and a pharmacy partner fulfills the prescription, rather than leaving you to source an unregulated peptide product and self-dose without any of the safety checks the trials actually built in. If you're weighing sourcing options you've seen online, read PT-141 peptide for sale Amazon first. Products sold that way skip every safety check described in this article.

Frequently asked questions

What were the RECONNECT trials for PT-141?

RECONNECT was the name given to two identical phase 3 randomized, placebo-controlled trials testing bremelanotide (PT-141) in premenopausal women with hypoactive sexual desire disorder, published in Obstetrics and Gynecology in 2019. They ran 24 weeks and formed the basis for FDA approval of Vyleesi ^[1].

Did PT-141 actually work in human trials?

It beat placebo on desire scores and distress measures with statistical significance, which supported FDA approval ^[1]. But independent reanalyses in the Journal of Sex Research argue the actual effect size was small and question how much real-world difference it makes for the average patient ^[20][24].

What is the most common PT-141 side effect in studies?

Nausea, affecting roughly 40% of participants across the pooled safety data from the bremelanotide clinical development program. Flushing was the next most common, at about 20% ^[11]. Both tend to be worse with early doses and often ease with continued use.

Is PT-141 approved for men?

No. Bremelanotide is FDA-approved only as Vyleesi for hypoactive sexual desire disorder in premenopausal women ^[4]. The RECONNECT trials enrolled only that population, so there's no equivalent approved trial evidence for men ^[1].

How is PT-141's mechanism different from Viagra?

Viagra-type drugs act on blood vessels to increase genital blood flow. PT-141 (bremelanotide) acts centrally, activating melanocortin receptors (mainly MC4R) in the brain, thought to influence dopamine-driven desire pathways rather than local blood flow ^[7][18].

Does PT-141 cause weight loss?

It's not approved or studied as a weight loss drug, but because it acts on melanocortin receptors also involved in appetite, a 2022 study in obese women found modest body weight changes during phase 1 trials ^[26]. That finding doesn't establish it as a metabolic treatment.

How many doses of PT-141 can you take per month?

In the RECONNECT trials and on the Vyleesi label, dosing was as-needed, at least 45 minutes before anticipated sexual activity, capped at one dose per 24 hours and generally no more than 8 doses per month ^[1][9]. Going beyond that wasn't studied.

Can PT-141 raise blood pressure?

Yes, it causes a transient increase in blood pressure after each dose, which is why it's not recommended for people with uncontrolled hypertension or cardiovascular disease ^[22]. Anyone on blood pressure medication should discuss this with a prescriber before starting.

How does PT-141 compare to flibanserin (Addyi)?

Both are FDA-approved for HSDD but work differently: flibanserin is a daily pill acting on serotonin/dopamine balance, while bremelanotide is an as-needed injection acting on melanocortin receptors ^[7][9]. A 2021 analysis argued both drugs' approvals rested on modest effect sizes ^[16].

Does PT-141 cause skin darkening?

Some users develop focal hyperpigmentation, darkened patches often on the face or gums, with repeated dosing. This is a documented finding tied to melanocortin receptor activity on pigment cells and is noted in FDA approval and safety literature ^[4][9].

Who was excluded from the PT-141 clinical trials?

The RECONNECT trials excluded postmenopausal women, men, people whose low desire was better explained by relationship issues or untreated depression, and people with uncontrolled hypertension or cardiovascular disease ^[1][2][22]. Results don't necessarily extend to those groups.

Is there long-term safety data on PT-141?

The core trial data covers about 24 weeks, with some extension safety follow-up, but published long-term data beyond roughly a year is limited. Reanalyses of the phase 3 program don't report extended long-term outcomes data ^[1][20][24].

Has PT-141 been studied for anything besides sexual desire?

Yes, in early lab research. A 2024 study found it inhibited glioblastoma cell growth in vitro via survivin suppression ^[23], and melanocortin receptor biology broadly is studied in metabolic disease and inflammation ^[6][17]. None of this is an approved or clinically established use.

Sources

1. Obstetrics and Gynecology, 2019 (PMID 31599840): The RECONNECT phase 3 trials tested bremelanotide 1.75 mg subcutaneous in premenopausal women with HSDD over 24 weeks and found statistically significant improvement in desire and distress versus placebo.
2. Journal of Midwifery & Women's Health, 2021 (PMID 34510696): HSDD diagnosis requires ruling out other causes of low desire such as relationship distress or another medical condition.
3. PubMed, 2006 (PMID 31369224): Early bremelanotide pharmacology work explored the compound before the injectable formulation was developed.
4. Drugs, 2019, Bremelanotide: First Approval (PMID 31429064): Bremelanotide received FDA approval as Vyleesi in 2019 for HSDD in premenopausal women, with focal hyperpigmentation noted as a documented effect.
5. Nature Reviews Endocrinology, 2023 (PMID 37365323): The central melanocortin system, the same target as bremelanotide, is also studied for metabolic disorders including appetite regulation.
6. CNS Spectrums, 2022, neurobiology of bremelanotide (PMID 33455598): Bremelanotide's mechanism involves melanocortin receptor activation influencing dopamine-related desire pathways in the brain, distinct from vascular drugs.
7. The Annals of Pharmacotherapy, 2020 (PMID 31893927): Bremelanotide's approved indication is specifically defined and limited to premenopausal women with HSDD.
8. The Urologic Clinics of North America, 2022 (PMID 35428435): Bremelanotide dosing regimen, drug interaction cautions (including naltrexone), and its place alongside flibanserin and non-drug therapies for female sexual dysfunction.
9. Current Psychiatry Reports, 2022 (PMID 35102537): Effective treatment selection for sexual dysfunction in women depends on correctly identifying the underlying cause of low desire.
10. Journal of Women's Health, 2022, Safety Profile of Bremelanotide (PMID 35147466): Pooled safety data across the bremelanotide clinical development program found nausea in roughly 40% and flushing in roughly 20% of participants.
11. Journal of Women's Health, 2022, RECONNECT subgroup analyses (PMID 35230162): Prespecified subgroup analyses across the RECONNECT trials examined whether treatment effects held across age and HSDD severity subgroups.
12. Drug and Therapeutics Bulletin, 2021 (PMID 34642243): A comparative analysis of bremelanotide and flibanserin approvals questioned whether the regulatory precedent reflected clinically meaningful effect sizes.
13. Diseases (Basel), 2025 (PMID 41002740): Melanocortin receptor gene polymorphisms have been studied for associations with inflammatory traits and disease.
14. Current Topics in Medicinal Chemistry, 2007 (PMID 17584134): Melanocortin receptor agonists including bremelanotide have documented interaction concerns with opioid antagonists like naltrexone.
15. Journal of Sex Research, 2024, Small Effects, Questionable Outcomes (PMID 36809187): An independent reanalysis argued the effect sizes in bremelanotide's phase 3 trials were small and of questionable clinical meaningfulness.
16. The Journal of Sexual Medicine, 2019, Phase 2b responder analysis (PMID 31277966): Phase 2b dose-ranging responder analyses established the 1.75 mg dose used in later phase 3 trials, balancing effectiveness against tolerability.
17. Medicina (Kaunas), 2022 (PMID 35630054): Bremelanotide causes a transient rise in blood pressure and requires caution in patients with hypertension or cardiovascular disease.
18. Anticancer Research, 2024 (PMID 39197897): Bremelanotide induced cell death and growth inhibition in glioblastoma cells in laboratory experiments via survivin suppression.
19. Journal of Sex Research, 2021, Re-Analyzing Phase III Bremelanotide Trials (PMID 33678061): A reanalysis of the phase 3 bremelanotide trials raised concerns about how treatment responders were defined in the original reporting.
20. Journal of Controlled Release, 2025 (PMID 40513668): Researchers have developed a dissolvable transbuccal patch as an alternative peptide delivery method to avoid injection.
21. Diabetes, Obesity and Metabolism, 2022 (PMID 35170192): Two phase 1 randomized controlled trials in obese women found modest body weight changes associated with bremelanotide.